{
    "id": 29057,
    "fullName": "SLFN11 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "SLFN11 loss indicates loss of the SLFN11 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 91607,
        "geneSymbol": "SLFN11",
        "terms": [
            "SLFN11",
            "SLFN8/9"
        ]
    },
    "variant": "loss",
    "createDate": "12/04/2018",
    "updateDate": "12/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15330,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells with targeted loss of SLFN11 demonstrated resistance to treatment with Talzenna (talazoparib) in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15337,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Talzenna (talazoparib) to Temodar (temozolomide) treatment resulted in no benefit in MGMT-proficient leukemia cells with targeted loss of SLFN11 when compared to Temodar (temozolomide) treatment alone (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15331,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leukemia cells with targeted loss of SLFN11 demonstrated resistance to treatment with Talzenna (talazoparib) in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15329,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ewing's sarcoma cells with targeted loss of SLFN11 demonstrated resistance to treatment with Lynparza (olaparib) in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15339,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Talzenna (talazoparib) resulted in a synergistic effect in prostate cancer cells with targeted loss of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 7562,
                "therapyName": "Talazoparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15336,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Talzenna (talazoparib) to Temodar (temozolomide) treatment resulted in no benefit in MGMT-proficient prostate cancer cells with targeted loss of SLFN11 when compared to Temodar (temozolomide) treatment alone (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15327,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells with targeted loss of SLFN11 demonstrated resistance to treatment with Lynparza (olaparib) in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Talzenna (talazoparib) resulted in a synergistic effect in leukemia cells with targeted loss of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 7562,
                "therapyName": "Talazoparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15338,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Talzenna (talazoparib) to Temodar (temozolomide) treatment resulted in no benefit in MGMT-proficient Ewing's sarcoma cells with targeted loss of SLFN11 when compared to Temodar (temozolomide) treatment alone in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15332,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ewing's sarcoma cells with targeted loss of SLFN11 demonstrated resistance to treatment with Talzenna (talazoparib) in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15328,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leukemia cells with targeted loss of SLFN11 demonstrated resistance to treatment with Lynparza (olaparib) in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15344,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Lynparza (olaparib) resulted in a synergistic effect in Ewing's sarcoma cells with targeted loss of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 7563,
                "therapyName": "Olaparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Lynparza (olaparib) resulted in a synergistic effect in prostate cancer cells with targeted loss of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 7563,
                "therapyName": "Olaparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15343,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Lynparza (olaparib) resulted in a synergistic effect in leukemia cells with targeted loss of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 7563,
                "therapyName": "Olaparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15341,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Talzenna (talazoparib) resulted in a synergistic effect in Ewing's sarcoma cells with targeted loss of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 7562,
                "therapyName": "Talazoparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30987,
            "profileName": "SLFN11 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}